Alzheimer's disease (AD) remains a foremost challenge in neurodegenerative research, with cholinesterase inhibition representing a pivotal mechanism in symptomatic treatment. Inhibitors of ...
A patent from Centre National de la Recherche Scientifique (CNRS), McGill University and Sorbonne University discloses new acetylcholinesterase (AChE) inhibitors reported to be useful for the ...
“This work provides new opportunities for the development of the next generation of ChE inhibitors that specifically target AChE and BChE associated with AD pathology.” “This work provides new ...
Aché Laboratórios Farmacêuticos SA has identified compounds acting as sodium/glucose cotransporter 1 (SGLT-1), SGLT-2 and dipeptidyl peptidase 4 (DPP4; CD26) inhibitors reported to be useful for the ...
Opportunities in the pain market include developing NaV inhibitors like NaV1.8 and NaV1.7, diversifying pain therapeutics by molecule type, and capitalizing on the fast-growing nociceptive pain sector ...
On July 29, 2024, the U.S. FDA approved Alpha Cognition Inc.'s ALPHA-1062 (Zunveyl ®), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer’s disease. This condition ...
Neuropathic pain is a devastating type of pain that significantly reduces the quality of life of affected people.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results